AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

AptarGroup, Inc.NYSE: ATR

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures declines year over year

Q2 FY2026 capital expenditures of $57.56M (cash outflow) fell 11.4% year over year, behind the -0.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 12.0% from the prior quarter. Over 3 fiscal years it compounded at -5.0% a year.

Context

  • Capital expenditures amounted to 7.2% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -11.4% toward the trailing-twelve-month pace of -0.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$57.56M-12.0% QoQ
Last fiscal yearDec 2025
-$270.42M-8.1% YoY
LTMJun 2026
-$273.09M-0.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year-8.1%——
3-year CAGR-5.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(270.42M) USD
Year-over-year change
+8.1%

Capital Expenditures vs competitors

How ATR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.6% is the 3rd highest of 7, against a peer median of -26.0%.
  • Capital expenditures amounts to 6.9% of revenue for ATR, versus a peer median of 4.6%.
ATR Competitors
Capital Expenditures for ATR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMCRAmcor plcLTM Jun 2026$505.47M USD+129.8%+20.6%2.2%
SLGNSilgan Holdings Inc.LTM Jun 2026$298.09M USD+3.9%+12.5%4.5%
ATRAptarGroup, Inc.LTM Jun 2026$273.09M USD-0.6%-5.0%6.9%
STVNStevanato Group S.p.A.LTM Jun 2026€272.65M EUR-38.5%+1.4%22.3%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$225.3M USD-32.3%+0.2%6.8%
SONSonoco Products CompanyLTM Sep 2026$218.55M USD-41.7%+1.5%3.0%
TRSTriMas CorporationLTM Mar 2026$40.63M USD-19.8%+1.7%4.7%
Peer median (excluding ATR) —-26.0%+1.6%4.6%

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income243.64M239.56M284.18M374.18M392.79M
Depreciation & Amortization234.85M233.71M248.59M263.78M287.36M
Deferred Income Tax(14.36M)(12.11M)(19.88M)(21.41M)(11.69M)
Stock-Based Compensation38.87M40.94M41.29M47.65M0
Change in Working Capital(169.7M)(45M)5.75M(32.26M)(125.45M)
Accounts Receivables(123.25M)(27.94M)15.43M(18.08M)(73.89M)
Inventory(79.96M)(60.35M)(10.64M)21.9M(10.65M)
Accounts Payables52.31M55.1M14.6M(23.71M)(18.27M)
Other Working Capital(18.79M)(11.8M)(13.64M)(12.38M)(22.64M)
Other Non-Cash Items30.13M21.52M15.31M11.47M26.99M
Operating Cash Flow363.44M478.62M575.24M643.41M570M
Capital Expenditures(307.94M)(315.62M)(318.4M)(294.19M)(270.42M)
Acquisitions (Net)(148.42M)(4.1M)(16.57M)0(55.87M)
Purchases of Investments(7.37M)00(101.3M)(8.66M)
Sales of Investments2.43M2.34M5.6M05.77M
Other Investing Activities4.05M21.74M4.91M(1.23M)3.56M
Investing Cash Flow(457.24M)(295.64M)(324.46M)(396.72M)(330.64M)
Debt Repayment36.95M4.99M(51.55M)(97.46M)388.64M
Common Stock Issued000018.89M
Common Stock Repurchased(78.15M)(92.13M)(47.55M)(68.64M)(365.01M)
Dividends Paid(98.51M)(99.46M)(103.68M)(114.06M)(120.78M)
Other Financing Activities58.19M24.5M31.23M54.81M0
Financing Cash Flow(81.52M)(162.1M)(171.55M)(225.34M)(78.26M)
Effect of Forex Changes(6.73M)(1.07M)2.19M(21.15M)16.98M
Net Change in Cash(182.05M)19.81M81.41M201K178.08M
Free Cash Flow55.51M163M256.84M349.22M299.58M

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.